Clinical & Experimental Allergy Building the investment case for asthma R&D: the European Asthma Research and Innovation Partnership argument S. M. Walker, C. Akdis, S. E. Dahlen, R. Djukanovic, J. Edwards, L. Garcia-Marcos, S. Johnston, M. Kupczyk, T. Martin, D. Myles, S. Palkonen, N. Papadopoulos, P. Powell and J. Riley Research & Policy, European Asthma Research & Innovation Partnership, Asthma UK, London, UK, Swiss Institute of Allergy and Asthma Research (SIAF), Medical Faculty, University of Zurich, Zurich, Switzerland, Asthma and Allergy Research, IMM Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Department of Medicine, Southampton NIHR Respiratory Biomedical Research Unit, University of Southampton, Department of Paediatrics, Paediatric Respiratory and Allergy Units, Arrixaca University Children’s Hospital, University of Murcia, Murcia, Spain, Department of Respiratory Medicine, Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, UK, Medical University of Ł od z, Ł od z, Poland, Respiratory Therapeutic Area, Respiratory Franchise, Novartis Pharmaceuticals, East Hanover, NJ, USA, Asthma Clinical Discovery, Respiratory Therapy Area Unit, GlaxoSmithKline, Hertfordshire, UK, European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), Brussels, Belgium, Allergy Department, University of Athens, Athens, Greece, Allergy & Paediatric Allergy, University of Manchester, Manchester, European Lung Foundation, Sheffield, UK